Nutrafol vs minoxidil has a clearer answer when the cause is pattern hair loss: topical minoxidil is the better-supported first choice. Nutrafol may suit an adult who prefers an oral supplement and accepts weaker, formula-specific evidence. No published randomized head-to-head trial was found through November 7, 2026, so percentages from separate studies can't prove which grows more hair. This desk comparison uses current U.S. labels checked the same day and covers topical, not prescription oral, minoxidil.
| Decision point | Nutrafol | Topical minoxidil |
|---|---|---|
| Product type | Multi-ingredient oral dietary supplement; formulas vary by life stage and sex | Over-the-counter topical drug; this comparison focuses on 5% foam |
| Best-supported use | An optional supplement after the cause of thinning is assessed | Male or female pattern hair loss that fits the product label |
| Current U.S. use | Core formulas use 4 capsules once daily; exact ingredients vary | Women: half a capful once daily; men: half a capful twice daily |
| Evidence base | Small, product-specific trials, mostly funded by the manufacturer | Multiple randomized trials and systematic reviews across men and women |
| Time to assess | Manufacturer claims visible results in 3-6 months | Label says 2-4 months for men and 3-6 months for women |
| Main drawbacks | Four pills, several actives, allergy and interaction questions, uncertain formula transfer | Scalp irritation, unwanted facial hair, possible early shedding, daily application |
| After stopping | Durability after stopping hasn't been established | The label says continued use is needed to keep regrowth |
What the trials actually show
Minoxidil has the wider evidence base. Olsen and colleagues randomized 393 men with androgenetic alopecia to 5% minoxidil, 2% minoxidil or placebo for 48 weeks. Five percent worked sooner and produced 45% more regrowth than 2% at week 48, but it caused more itching and local irritation. The trial used solution twice daily, not today's foam schedules.
A 2016 Cochrane review by van Zuuren, Fedorowicz and Schoones included 47 trials and 5,290 women, 17 of which evaluated minoxidil. Across six pooled studies, 157 of 593 minoxidil users reported moderate-to-marked regrowth. The figure was 77 of 555 with placebo, giving a risk ratio of 1.93 with moderate-quality evidence.
Nutrafol has positive trials, but they are smaller. Ablon and Kogan's 2018 placebo-controlled Nutrafol Women trial enrolled 40 women: 26 received the supplement and 14 received placebo. Hair counts and blinded assessments favored Nutrafol at 90 and 180 days, but the trial tested an earlier formula.
The men's evidence is newer but limited: Bhatia and colleagues enrolled 112 men, and 85 finished the 2025 trial. At day 180, blinded investigators rated growth improved in 79% on Nutrafol and 51% on placebo. Protocol deviations made the planned hair-count endpoint unusable, and Nutrafol funded the study. Every author reported a company relationship.
The current Women Advanced formula appeared in a 2026 open-label study. Dang and colleagues enrolled 180 women across four Nutrafol formulas, and 150 completed it. Hair-growth measures improved from baseline, but there was no placebo or minoxidil group, and participants knew what they took. Nutraceutical Wellness funded the study, and two authors were employees.
A 2026 review by Alanazi and colleagues pooled 14 studies with 967 participants. It combined eight different commercial supplements, so its average doesn't isolate Nutrafol. Total hair count wasn't significantly better than placebo, while several growth-cycle outcomes favored supplements. The authors called the evidence preliminary and asked for independent trials.
Feldman and colleagues' 2023 network meta-analysis is the closest published comparison, but it modeled separate placebo-controlled trials instead of randomizing people between treatments. That can generate a ranking, not a head-to-head result, and it used only one Nutrafol study in women. It can't establish that today's formula is equal or superior to minoxidil.
Current formulas and label claims
Nutrafol is a product family, not one fixed treatment. Its U.S. pages divide formulas by sex and life stage: Women Advanced is for women 18-44, while Nutrafol Men is for men 18-49.
Women Advanced provides a 2.5 g proprietary blend in four vegan capsules taken once daily. Nutrafol lists saw palmetto, ashwagandha, curcumin, tocotrienols and Moldavian dragonhead, plus Bacillus subtilis, pea sprout and bamboo. The maker claims less shedding and faster, stronger, longer hair within 3-6 months.
Nutrafol Men provides a 1.72 g Synergen Complex and 575 mg Nutrafol blend in four capsules taken once daily with a meal. Its highlighted ingredients are saw palmetto, ashwagandha, curcumin, tocotrienols, marine collagen and hyaluronic acid. The page claims less shedding and fuller scalp coverage within 3-6 months.
Those are manufacturer claims, not comparative findings. Many botanicals sit inside proprietary blends, so the labels don't disclose every ingredient's dose. This also makes an old formula's trial harder to apply to a revised product.
Women's current U.S. foam contains minoxidil 5% w/w and uses half a capful once daily on the top of the scalp. Men's foam contains the same strength and uses half a capful twice daily on the vertex. The men's label doesn't claim treatment for frontal baldness or a receding hairline.
How long should you give either option?
Neither is a quick cosmetic fix: the women's minoxidil label says results may appear at 3 months, but some women need 6 months. The men's label says results may appear at 2 months, but some men need 4 months; using more won't speed this up.
Nutrafol's current U.S. pages claim results in 3-6 months, matching its study schedule but not guaranteeing visible change. For a month-by-month view, see the evidence timeline for minoxidil results.
Take baseline photos before you start, keeping the part, camera distance, lighting and wetness consistent. If your concern is the temples or front outline, the hairline scan can compare visible outline changes in repeatable photos. It can't diagnose the cause or prove a treatment worked.
Side effects and practical tradeoffs
Minoxidil can irritate the scalp and cause unwanted facial hair. An early change in shedding can be confusing; the minoxidil shedding guide explains the usual timing and warning signs. Stop and seek medical advice for chest pain, rapid heartbeat, faintness, dizziness, swelling or sudden unexplained weight gain.
Nutrafol avoids scalp application, but “natural” doesn't mean interaction-free. In the men's trial, possibly related digestive effects occurred in three active users and three placebo users, and one person in each group withdrew. Short trials also can't reliably detect rare problems.
Formula details matter: current Nutrafol Men contains fish-derived marine collagen and 3,000 mcg of biotin per serving. Current Women Advanced is vegan and says biotin was removed. High supplemental biotin can distort some thyroid, vitamin D and cardiac blood tests, the NIH warns. Tell the clinician and laboratory what you take before testing.
Minoxidil labels warn against use during pregnancy or breastfeeding, while Nutrafol formulas have ingredient-specific restrictions. A clinician should review any oral supplement if you're pregnant, breastfeeding, managing a chronic condition or taking medicines.
How to choose without wasting six months
Illustrative examples:
- A man with gradual crown thinning, family history and a healthy scalp matches the minoxidil trial populations more closely.
- A woman with sudden diffuse shedding after an illness doesn't fit either evidence base, so the trigger and diagnosis come first.
- An adult with confirmed pattern loss who refuses scalp treatment may prefer Nutrafol, but that preference doesn't make its evidence equivalent.
Choose the routine you can sustain, then change one major variable at a time because starting both together makes improvement hard to attribute. If pattern loss is confirmed, the guide to why treatment timing matters explains the cost of waiting.
When a clinician should make the call
Get assessed before choosing either option if loss is sudden, patchy, postpartum or unexplained. The same applies when the scalp is red, painful, infected or heavily scaled because these patterns may need a diagnosis.
A clinician should also decide if you're under 18, pregnant, breastfeeding, have heart disease or take prescription medicines. Bring the exact supplement label because formula names alone don't reveal every ingredient or interaction.
For confirmed pattern hair loss, topical minoxidil remains the evidence-first choice when its label fits you. Nutrafol is an optional supplement for someone who accepts lower certainty and a multi-ingredient oral product. A professional should make the final call whenever the diagnosis, safety or treatment fit is unclear.
Oscar Nascimento
Editorial writer, GlowUp Face
Oscar writes about evidence-based skin care, healthcare, looksmaxxing, and the social and economic research surrounding appearance.
Full profile and all articles →
